147 related articles for article (PubMed ID: 6652630)
1. Mitoxantrone: modest activity in a phase II trial in advanced prostate cancer.
Osborne CK; Drelichman A; Von Hoff DD; Crawford ED
Cancer Treat Rep; 1983 Dec; 67(12):1133-5. PubMed ID: 6652630
[TBL] [Abstract][Full Text] [Related]
2. Phase II trial of mitoxantrone in multiple myeloma: a Southwest Oncology Group Study.
Alberts DS; Balcerzak SP; Bonnet JD; Stephens RL
Cancer Treat Rep; 1985 Nov; 69(11):1321-3. PubMed ID: 4092195
[TBL] [Abstract][Full Text] [Related]
3. [A phase II study of mitoxantrone in refractory and relapsed malignant lymphomas. Cooperative Study Group of Mitoxantrone in Malignant Lymphomas].
Kimura I; Ohnoshi T; Ogawa M; Sampi K; Masaoka T; Yamada K; Ohta K; Kitani T; Kawagoe H; Shirakawa S
Gan To Kagaku Ryoho; 1986 Sep; 13(9):2800-6. PubMed ID: 3753026
[TBL] [Abstract][Full Text] [Related]
4. A phase II study of mitoxantrone in advanced breast cancer.
Pronzato P; Ardizzoni A; Conte PF; Gulisano M; Lionetto R; Repetto L; Scornavacche V; Sertoli MR; Rosso R
Chemioterapia; 1986 Jun; 5(3):150-3. PubMed ID: 3719852
[TBL] [Abstract][Full Text] [Related]
5. Phase II trial of mitoxantrone in previously untreated patients with colorectal adenocarcinoma: A Southwest Oncology Group Study.
Cowan JD; Von Hoff DD; McDonald B; Talley RW; McCracken JD; Chen T
Cancer Treat Rep; 1982 Sep; 66(9):1779-80. PubMed ID: 7116355
[No Abstract] [Full Text] [Related]
6. Phase II study of mitoxantrone and ketoconazole for hormone-refractory prostate cancer.
Eklund J; Kozloff M; Vlamakis J; Starr A; Mariott M; Gallot L; Jovanovic B; Schilder L; Robin E; Pins M; Bergan RC
Cancer; 2006 Jun; 106(11):2459-65. PubMed ID: 16615097
[TBL] [Abstract][Full Text] [Related]
7. Clinical and clinical pharmacologic studies of mitoxantrone.
Stewart JA; McCormack JJ; Krakoff IH
Cancer Treat Rep; 1982 Jun; 66(6):1327-31. PubMed ID: 7083236
[TBL] [Abstract][Full Text] [Related]
8. Phase II trial of mitoxantrone in advanced colorectal cancer.
Bonnem EM; Mitchell EP; Woolley PV; Smith FP; Neefe J; Smith L; Schein PS
Cancer Treat Rep; 1982 Nov; 66(11):1995-6. PubMed ID: 7139642
[No Abstract] [Full Text] [Related]
9. Phase II trial of tesmilifene plus mitoxantrone and prednisone for hormone refractory prostate cancer: high subjective and objective response in patients with symptomatic metastases.
Raghavan D; Brandes LJ; Klapp K; Snyder T; Styles E; Tsao-Wei D; Lieskovsky G; Quinn DI; Ramsey EW
J Urol; 2005 Nov; 174(5):1808-13; discussion 1813. PubMed ID: 16217292
[TBL] [Abstract][Full Text] [Related]
10. [Phase II study of mitoxantrone].
Tada A; Ogawa M; Usui N; Inagaki J; Horikoshi N; Inoue K; Ikeda K; Adachi K; Nakada H; Okada Y
Gan To Kagaku Ryoho; 1984 Aug; 11(8):1649-54. PubMed ID: 6476838
[TBL] [Abstract][Full Text] [Related]
11. Phase I study of a 5-day schedule of mitoxantrone (dihydroxyanthracenedione).
Wynert WR; Harvey HA; Lipton A; Schweitzer J; White DS
Cancer Treat Rep; 1982 Jun; 66(6):1303-6. PubMed ID: 7083234
[TBL] [Abstract][Full Text] [Related]
12. Phase II evaluation of mitoxantrone in advanced carcinoma of the stomach: a Southeastern Cancer Study Group Trial.
DeSimone PA; Gams R; Birch R
Cancer Treat Rep; 1986 Aug; 70(8):1043-4. PubMed ID: 3524836
[No Abstract] [Full Text] [Related]
13. Phase II evaluation of dihydroxyanthracenedione (DHAD, NSC 301739) in patients with metastatic colorectal cancer.
Bedikian AY; Stroehlein J; Korinek J; Karlin D; Valdivieso M; Bodey GP
Am J Clin Oncol; 1983 Feb; 6(1):45-8. PubMed ID: 6837506
[TBL] [Abstract][Full Text] [Related]
14. Tamoxifen in refractory metastatic carcinoma of the prostate.
Glick JH; Wein A; Padavic K; Negendank W; Harris D; Brodovsky H
Cancer Treat Rep; 1980; 64(6-7):813-8. PubMed ID: 7427966
[TBL] [Abstract][Full Text] [Related]
15. [Phase II study of mitoxantrone in advanced breast cancer].
Ogawa M; Kubo K; Tominaga T; Nomura Y; Ota K; Yoshida M; Taguchi T; Hoshino A
Gan To Kagaku Ryoho; 1986 May; 13(5):1980-4. PubMed ID: 3707156
[TBL] [Abstract][Full Text] [Related]
16. Phase I investigation of ametantrone.
Loesch DM; Von Hoff DD; Kuhn J; Coltman CA; Tio F; Chaudhuri TK; Bender JF; Grillo-Lopez AJ
Cancer Treat Rep; 1983 Nov; 67(11):987-91. PubMed ID: 6640557
[TBL] [Abstract][Full Text] [Related]
17. A multicenter phase II trial of losoxantrone (DuP-941) in hormone-refractory metastatic prostate cancer.
Huan SD; Natale RB; Stewart DJ; Sartiano GP; Stella PJ; Roberts JD; Symes AL; Finizio M
Clin Cancer Res; 2000 Apr; 6(4):1333-6. PubMed ID: 10778959
[TBL] [Abstract][Full Text] [Related]
18. Prostate specific antigen response to mitoxantrone and prednisone in patients with refractory prostate cancer: prognostic factors and generalizability of a multicenter trial to clinical practice.
Dowling AJ; Czaykowski PM; Krahn MD; Moore MJ; Tannock IF
J Urol; 2000 May; 163(5):1481-5. PubMed ID: 10751862
[TBL] [Abstract][Full Text] [Related]
19. Phase II clinical trial of mitoxantrone in patients with advanced renal cell carcinoma: a Southwest Oncology Group study.
Taylor SA; Von Hoff DD; Baker LH; Balcerzak SP
Cancer Treat Rep; 1984 Jun; 68(6):919-20. PubMed ID: 6733708
[No Abstract] [Full Text] [Related]
20. A phase I dose-finding study of combined treatment with an antisense Bcl-2 oligonucleotide (Genasense) and mitoxantrone in patients with metastatic hormone-refractory prostate cancer.
Chi KN; Gleave ME; Klasa R; Murray N; Bryce C; Lopes de Menezes DE; D'Aloisio S; Tolcher AW
Clin Cancer Res; 2001 Dec; 7(12):3920-7. PubMed ID: 11751483
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
